HelenCollinsMD

Physician

Dr. Collins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
121 Sotoyome St
Santa Rosa, CA 95405
Phone+1 707-546-4062

Fax+1 707-525-4071

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1992 - 1995
Johns Hopkins UniversityResidency, Internal Medicine, 1988 - 1991
Johns Hopkins University School of MedicineClass of 1988

PubMed

80 citations
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Vikas Gupta, Ruben A. Mesa, Michael W. Deininger, Candido E. Rivera, Shireen Sirhan
Haematologica. 2017-01-01
69 citations
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 s...
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi
The Lancet. Oncology. 2022-11-01
11 citations
Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
Robert Pirker, Melissa Pirolli, Jane M Quigley, Scott Hulnick, Jason C. Legg
Supportive Care in Cancer. 2013-04-01

Prime Time for Five Prime as Amgen Snaps up This Once-Moribund Biotech for $1.9B and Its Phoenix-from-the-Flames Cancer AssetMarch 4th, 2021
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ CancersJanuary 15th, 2021
Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer TrialNovember 13th, 2020
Join now to see all